With the help of computational pathology firm Paige, healthcare technology giant Royal Phillips is bringing clinical artificial intelligence to pathology laboratories to help improve a pathologist’s workflow and treatment planning for patients.
According to a joint news release Thursday, this strategic collaboration will first start with Paige Prostate to help pathologists quantify and characterize cancer in tissue samples and make precise and efficient diagnoses.
The release noted the need for more advanced cancer diagnosis technology as the number of cancer cases rises. Glass slide-based laboratory workflows are being converted to digital using solutions like ones offered by Phillips.
Once digital images are created, the CE-marked Paige Prostate software is applied automatically to detect and localize prostate cancer, providing pathologists with valuable information they can use to evaluate prostate biopsies.
“We want to empower pathologists with the latest computational pathology solutions to enhance the diagnosis and treatment of cancer,” said Marlon Thompson, business leader of digital & computational pathology at Philips, in a statement.
“Through our open digital pathology platform approach, we team up with leading computational pathology solution providers, such as Paige, to create the ultimate end-to-end oncology workflow for our customers.”
Paige CEO Leo Grady said in the news release that pathology is becoming increasingly digital, which opens the door for AI solutions to help diagnose cancers and improve decision-making.
“Together with digital pathology providers, starting with Philips, one of the leaders in the clinical digital pathology space, we want to convert this promise into a clinical reality that supports pathologists and their patients,” Grady said.
Phillips plans to offer the Paige Prostate with its IntelliSite Pathology Solition to pathology labs in Europe in 2020. Smart solutions for other markets and diseases will be released after that.